Eltrombopag (Eltrombopag) is a prescription medicine used to treat low blood platelet counts (thrombocytopenia) in adults and children. It belongs to a class of drugs known as thrombopoietin receptor agonists (TPO-RAs). It works by stimulating the bone marrow to produce more platelets, which are essential for blood clotting. It is primarily indicated for patients with chronic immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, and severe aplastic anemia. It is available as an oral tablet or for oral suspension.

Eltrombopag (eltrombopag) is a medicine used to treat low platelet counts (thrombocytopenia). Platelets are blood cells that help control bleeding by forming clots. This medicine is commonly prescribed for conditions such as chronic immune thrombocytopenia (ITP), severe aplastic anemia, and low platelet counts linked to chronic hepatitis C in selected patients.

Eltrombopag works by stimulating the bone marrow to produce more platelets. By raising platelet levels, it may help reduce the risk of bleeding, bruising, and related complications in people whose platelet counts are too low.

The medicine does not cure the underlying condition causing low platelets, but it can help manage symptoms and improve platelet stability during treatment. Patients may notice fewer bleeding episodes and better control of symptoms when the medicine is used as prescribed.

Eltrombopag is taken by mouth and should be used exactly as directed by a healthcare professional. Regular blood tests are usually needed to monitor platelet counts and liver function during treatment. Certain foods, mineral supplements, and antacids containing calcium, iron, magnesium, or aluminum can affect absorption, so the medicine may need to be taken at a different time from these products.

Eltrombopag may be indicated by your doctor for:

Chronic Immune Thrombocytopenia (ITP)

For patients who have had an insufficient response to corticosteroids, immunoglobulins, or spleen removal.

Chronic Hepatitis C-associated Thrombocytopenia

To increase and maintain platelet counts so that interferon-based therapy can be initiated and continued.

Severe Aplastic Anemia (SAA)

For patients who have not responded adequately to immunosuppressive therapy, or in combination with standard therapy as a first-line treatment.

Refractory Thrombocytopenia

Management of low platelets in specific bone marrow disorders as determined by a specialist.

Eltrombopag may provide benefits such as:

• Bleeding Prevention: Reduces the frequency and severity of bleeding episodes by maintaining safer platelet levels.

• Avoidance of Surgery: May help patients avoid or delay the surgical removal of the spleen (splenectomy).

• Oral Convenience: Unlike some other TPO agonists that require injections, this is a once-daily oral medication.

• Treatment Continuity: Allows patients with Hepatitis C to stay on antiviral medications that would otherwise be stopped due to low platelets.

• Bone Marrow Support: Directly stimulates the body's natural platelet-making machinery.

Common side effects of Eltrombopag may include

• Nausea and diarrhea

• Headache

• Muscle aches or back pain

• Tiredness (fatigue)

• Flu-like symptoms or sore throat

Uncommon side effects of Eltrombopag may include

• Tingling or numbness in hands and feet

• Skin rash or itching

• Dry eye or blurred vision

• Indigestion or loss of appetite

Serious side effects that require medical attention may include

• Liver Toxicity: Yellowing of the skin or eyes (jaundice), dark urine, or unusual pain in the upper right stomach area.

• Blood Clots: Swelling, pain, or tenderness in one leg; sudden shortness of breath; or chest pain.

• Vision Changes: New or worsening clouding of the lens in the eye (cataracts).

• Worsening Bone Marrow Conditions: Changes in blood cell shapes or progression of certain pre-cancerous conditions (MDS).

Consult your doctor if you experience any unusual, severe, or persistent symptoms while using Eltrombopag.

• Take Eltrombopag exactly as prescribed by your doctor, as the dose is adjusted based on your platelet counts and medical condition.

• Swallow the tablet with water, usually once daily, at the same time each day for consistent effect.

• Take it on an empty stomach, at least 1 hour before or 2 hours after food, as food can affect absorption.

• Avoid taking it at the same time as products containing calcium, iron, magnesium, aluminium, or zinc; keep a time gap as advised by your doctor.

• Regular blood tests are needed during treatment to monitor platelet levels and liver function, and your dose may be changed based on results.

• Do not stop or change the dose without medical advice, even if you feel well.

Eltrombopag is a thrombopoietin (TPO) receptor agonist that helps the body produce more platelets. Platelets are important for normal blood clotting, and increasing their number can help reduce the risk of bleeding in people with low platelet counts.

Eltrombopag works by binding to the thrombopoietin receptor (Tpo-R) on bone marrow cells. This activates signaling pathways such as JAK/STAT and MAPK, which are involved in blood cell production.

These signals stimulate the growth and maturation of megakaryocytes, the large bone marrow cells that produce platelets. As more megakaryocytes develop, platelet production gradually increases.

By supporting the body’s natural platelet production process, Eltrombopag helps compensate for reduced platelet formation or increased platelet destruction seen in conditions such as immune thrombocytopenia and certain bone marrow disorders.

• Take Eltrombopag exactly as prescribed and follow your doctor’s instructions carefully regarding dose adjustments and blood test monitoring.

• Eltrombopag should usually be taken on an empty stomach. Avoid taking it close to milk, calcium supplements, antacids, or iron products, as these can reduce how well the medicine is absorbed.

• Attend all scheduled blood tests while using Eltrombopag. Your doctor may monitor platelet counts and liver function during treatment.

• Report any unusual symptoms such as yellowing of the skin or eyes, dark urine, severe abdominal pain, or unusual bruising to your doctor promptly.

• Store at room temperature (15°C to 30°C).

• Keep in the original container, tightly closed.

• Protect from light and moisture.

• Keep out of reach of children.

• Dairy Products (Caution): Milk, cheese, yogurt, and ice cream significantly reduce absorption. Avoid near dose.

• Calcium-Fortified Foods (Caution): Some juices and cereals can interfere with the drug. Avoid near dose.

• High-Fat Meals (Caution): Taking the drug with a high-fat meal can also affect how much medicine gets into your system.

• Antacids (Caution): Products containing Calcium, Magnesium, or Aluminum must be spaced 4 hours apart from the dose.

• Statins (Caution): Eltrombopag can significantly increase levels of rosuvastatin; dose reduction of the statin may be needed.

• Mineral Supplements (Caution): Iron, Selenium, and Zinc supplements interfere with absorption.

• Blood Thinners (Caution): Use with Warfarin may require more frequent clotting time checks (INR).

• Hepatic Impairment (Caution): Increases the risk of drug accumulation and toxicity.

• Cataracts (Caution): May worsen existing eye lens clouding.

• Thrombosis Risk (Caution): Patients with a history of blood clots should be monitored very closely.

• Myelodysplastic Syndromes (MDS) (Unsafe): There is a risk that the drug could cause certain bone marrow cancers to progress.

If you miss a dose, skip it and take your next dose at the usual scheduled time the next day. Do not take more than one dose in a single day. If you miss multiple doses, contact your doctor for advice, as your bleeding risk may increase.